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INTRODUCTION
Dengue viral infections are one of the most important mosquito borne diseases in the world. 
They  may  be  asymptomatic  or  may  give  rise  to  undifferentiated  fever,  dengue  fever,  dengue 
hemorrhagic   fever or dengue shock syndrome. Annually, 100 million cases of dengue fever and half a 
million cases of DHF occur worldwide. 90 percent of DHF are children less than 15 years of age. At 
present, dengue is endemic in 112 countries in the world (1,2) . No vaccine is available for preventing 
this disease. Early recognition and prompt initiation of appropriate treatment are vital. Additional data 
about the disease lead to  implementation or alteration in public  health programs. Here,  I  made an 
attempt  to  study  the  clinical  profile  and  outcome  during  July  08  to  
July 09.
AIM
To  study the clinical profile and outcome of dengue fever in children.
                              
SUBJECTS AND METHODS
Children less than 12 years of age with clinical features of dengue (any acute febrile illness with 
one of the following : myalgia, head ache ,retro-orbital pain ,bleeding ,altered  sensorium, shock or low 
platelet  count)  presented  at  Institute  of  Social  Pediatrics,  Government  Stanley  Hospital,  Chennai 
between  5th July 2008 and 10th January 2009 were  registered  in  the  study.  Informed consent  was 
obtained and detailed history was taken. For all cases  ,the rapid Ig M, Ig G ELISA test was done at  
Government Stanley Hospital, Chennai. Children positive for Ig M alone or both Ig M and Ig G were 
followed  up  for  clinical  profile.  Cases  of  enteric  fever,  leptospirosis,  malaria  were  excluded  by 
appropriate  investigations.  The number  of  children  included based on the  above criteria  was 105. 
Children who were seropositive were classified on the basis of WHO criteria (2) as follows :
1. Dengue fever (DF): dengue seropositive without bleed.
2. Dengue fever with unusual bleed (DFB): dengue seropositive with bleeding tendencies, not 
satisfying WHO criteria for DHF.
3. Dengue hemorrhagic fever (DHF) : dengue seropositive with bleeds with evidence of plasma 
leakage.
4.  Dengue shock syndrome (DSS): DHF with evidence of peripheral circulatory failure.
Laboratory  investigations  carried  out  in  these  patients  included  hemoglobin,  blood  counts, 
hematocrit, liver function tests etc. Chest X ray was taken to demonstrate pleural effusion. Ultra sound 
abdomen was done to identify ascites, polyserositis and gall bladder wall thickening. CSF analysis was 
done  in  patients  with  convulsions,  meningeal  signs  and  altered  sensorium.  Cases  were  managed 
according to the WHO protocol (2) and outcome was analyzed, using chi-square or fisher’s exact test 
for proportions and analysis of variance for continuous data. The statistical package used was PEPI 
version 4.0 for windows (Abramson JH and Gahlinger PM , Sagebrush press, salt lake city). The results 
were compared with other studies. After analysis conclusions were arrived. 
                                          
LITERATURE REVIEW
EPIDEMIOLOGY
During the 19th century, dengue was considered a sporadic disease, causing epidemics at long 
intervals. However, dramatic changes in this pattern have occurred and currently, dengue ranks as the 
most  important  mosquito borne viral  disease in  the world.  In  the past  50 years,  its  incidence has 
increased 30-fold with significant outbreaks occurring in five of six World Health Organization (WHO) 
regions. At present,  dengue is endemic in 112 countries in the world(1, 2).Around 2.5 to 3 billion 
people, living mainly in urban areas of tropical and subtropical regions, are estimated to be at risk of 
acquiring dengue viral infections(2). Estimates suggest that annually 100 million cases of dengue fever 
and half a million cases of dengue haemorrhagic fever (DHF) occur in the world with a case fatality in 
Asian countries of 0.5%–3.5%(3 )Of those with DHF, 90% are children less than 15 years of age(2).
Although sporadic dengue fever was known for more than 200 years, reasons for the global 
resurgence of  epidemics  of  dengue fever  and DHF are  not  very clear(4).  Uncontrolled population 
growth,  unplanned and uncontrolled urbanization,  inadequate wastewater  management,  and lack of 
effective mosquito control have been implicated in the increased distribution and density of the vector 
and also the increased spread of the virus(4). However, microevolution of the dengue virus may have 
also contributed to the spread of more virulent strains around the world. In fact there is evidence that 
the more virulent genotypes of the virus are replacing the less virulent genotypes, which may explain 
the global emergence of dengue infections(2).
Epidemiological trends in South East Asia
          The first epidemic of DHF in South East Asia occurred in 1954 in Manila, Philippines. Following 
this, epidemics have occurred in nearly all countries in this region, and currently are a major public 
health problem in seven of them. The incidence of DHF has increased dramatically in recent years with 
approximately five times more cases reported since 1980 than in the previous 30 years(2). Although 
serological  surveys  conducted  in  Indonesia  showed  that  DEN-1  and  DEN-2  were  the  prevalent 
serotypes until the late 1980s, the DEN-3 serotype has been the predominant serotype in the recent 
outbreaks  (5).In  fact,  DEN-3  has  been  associated  with  severe  dengue  epidemics  and  it  has  been 
suggested that the DEN-3 virus may have certain characteristics that make it more virulent. Although 
DEN–4  has  been  isolated  in  almost  all  epidemics,  it  is  primarily  detected  in  secondary  dengue 
infections (6). DHF (with an attack rate in the range 300–440cases/100 000 population) is a leading 
cause of hospitalization in children in South East Asia. While this rate has now fallen in Thailand (95–
103 cases/100 000 population in 1997),(7)some countries such as Vietnam, still experience very high 
attack rates(8) Although case fatality rates in most countries in South East Asia have declined and are 
now less than 1%, those in some countries still exceed 4%, mainly due to late admission to hospital, 
when the disease is at an advanced state(9) In the newly industrialized countries such as Singapore and 
Malaysia, successful vector control programmes led to a gradual decline in the incidence of dengue, but 
even here a resurgence has been seen since 1994(9).
Epidemiological trends in South Asia
 Although small outbreaks of DHF occurred South Asia between 1964 and 1966,(10) the first 
major epidemic of DHF occurred in Sri Lanka in 1989. Since then regular epidemics have occurred in 
Sri Lanka, resulting in increasing numbers of cases each year. The DEN-3 subtype III was identified as 
the  cause  of  the  first  and subsequent  epidemics  in  Sri  Lanka along with  the  DEN-2 serotype(11)  
Dengue infections were first  reported in India in 1991 (6291 cases of dengue fever),  and the first  
epidemic of DHF occurred in Delhi in 1996(11). 
Epidemiological pattern of DHF in South Asia is now similar to SEAR.
WORLD DISTRIBUTION OF PREDOMINANT DENGUE MOSQUITO VECTOR (Aedes 
aegypti) AND AREAS WITH DENGUE EPIDEMIC ACTIVITY.
CHARACTERISTICS OF DENGUE VIRUS:
The dengue virus is a single stranded RNA virus belonging to the flaviviridae family(4)There 
are four serotypes (DEN 1–4), classified according to biological and immunological criteria. The viral 
genome is  approximately 11  kb  in  length(4)  The  mature  virion  consists  of  three  structural  (core, 
membrane associated, and envelope) and seven non-structural (NS1,NS2a, NS2b, NS3, NS4a, NS4b, 
and NS5) proteins. The envelope protein is involved in the main biological functions of the virus.
Non-structural proteins (NS1–NS5) expressed as both membrane associated and secreted forms 
have also been implicated in the pathogenesis of severe disease. Unlike other viral glycoproteins, NS1 
does not form a part  of the virion but gets  expressed on the surface of infected cells.  Preliminary 
evidence suggests its involvement in viral RNA replication (12).
Plasma levels of secreted NS1 (sNS1) correlate with viral titers, being higher in patients with 
DHF compared with dengue fever (12). Moreover, elevated free sNS1 levels within 72 hours of onset 
of illness identify patients at risk of developing DHF. Very high levels of NS1 protein are detected in 
acute phase samples from patients with secondary dengue infections but not primary infections. This 
suggests that NS1 may contribute to formation of circulating immune complexes, which are thought to 
have an important role in the pathogenesis of severe dengue infections (4).The dengue virus shares 
antigenic epitopes with other flaviviruses such as Japanese encephalitis virus. These shared epitopes 
may lead to production of cross reactive antibodies and hence interfere with serological diagnosis. 
However,antibodies  directed  to  the  prM protein  of  dengue  viruses  are  species  specific  (not  cross 
reactive with those of other flaviviruses) and may be useful for seroepidemiological studies in dengue 
(especially in countries where other flaviviruses are endemic)(13).
MOSQUITO VECTORS
Mosquitoes  belonging  to  the  genus  aedes  (Aedes  aegypti,  Aedes  albopictus,  and  Aedes 
polynesiensis)  play an important  part  in  transmission of  dengue.  The primary and most  important 
vector  is  A aegypti,  but  A albopictus  and  A.polynesiensis  may  act  as  vectors  depending  on  the 
geographic location(2 ).For instance, A .albopictus has been found to sometimes transmit dengue in 
Thailand, Samui island, India, Singapore, and Mexico.
Aedes aegypti, a container breeding, day biting mosquito is found in tropical and subtropical 
areas(14). They rest indoors, mainly in living rooms and bedrooms. This maximizes man-vector contact 
and  minimizes  contact  with  insecticides  sprayed  outdoors,  hence  contributing  to  difficulty  in 
controlling this vector(15).
Significant increases in the mosquito larval populations are seen during the rainy season. This 
may be a reason why epidemics of dengue tend to coincide with the rainy season(14).Furthermore, 
ambient temperature and relative humidity affect viral propagation in mosquitoes; rates being highest 
in climates resembling the rainy season(14). Environmental temperatures also affect the time to acute 
viraemia in female mosquitoes, being shorter with rises in temperature (15).
 After biting an infected human, dengue viruses enter an adult female mosquito. The virus first 
replicates in the midgut, reaches the haemocoel and haemolymph, and then gains access to different 
tissues of the insect. After viral replication in the salivary glands, the infected mosquito can transmit the 
virus  to  another  human (15).  Compared  with  uninfected  mosquitoes,  infected  ones  take  longer  to 
complete a blood meal. This may contribute to the efficiency of A .aegypti as a dengue viral vector.
CLINICAL MANIFESTATIONS
Dengue infections may be asymptomatic or give rise to undifferentiated fever, dengue fever, 
dengue hemorrhagic fever or dengue shock syndrome.
DIFFERENTIAL DIAGNOSIS OF DENGUE
• Infectious mononucleosis
• Chickengunya
• Coxsackie infections
• Rickettsial infections
• Rubella
• Parvo B 19 infections
• Leptospirosis
• Influenza
DIFFERENTIAL DIAGNOSIS OF DHF
• Leptospirosis
• Chickengunya
• Kawasaki disease
• Yellow fever
• Hanta viral infections
• Meningococcal sepsis.
Undifferentiated fever 
This  usually follows a  primary infection  but  may also  occur  during  a  secondary infection. 
Clinically it is indistinguishable from other viral infections.
Dengue fever
Dengue fever may occur either during primary or secondary infections. The onset is sudden 
with high fever, severe headache (especially in the retro-orbital area), arthralgia, myalgia, anorexia, 
abdominal discomfort, and sometimes a macular papular rash. The fever may be biphasic and tends to 
last for 2–7 days(16). Flushing, a characteristic feature is commonly observed on the face, neck, and 
chest. Coryza may also be a prominent symptom especially in infants(16).Younger children tend to 
present with coryza, diarrhoea,  rash and seizure, and less commonly with vomiting,  headache,  and 
abdominal pain(17)
Although,  haemorrhagic manifestations  are  uncommon in dengue fever,  petechiae ,  pupura, 
gastrointestinal bleeding, epistaxis, and gingival bleeding have been observed in some individuals(18). 
A positive tourniquet test has been reported in many individuals with dengue fever possibly due to 
reduced  capillary  fragility  (17).  Recovery  from  dengue  fever  is  usually  uneventful,  but  may  be 
prolonged especially in adults (2).
Dengue  haemorrhagic  fever  :  DHF  usually  follows  secondary  dengue  infections,  but  may 
sometimes follow primary infections, especially in infants. In such infants, maternally acquired dengue 
antibodies are presumed to enhance primary infections (19).
The fever lasts for 2–7 days and is followed by a fall in temperature to normal or subnormal  
levels. At this point, the patient may recover or progress to the phase of plasma leakage. Those who 
remain ill despite their temperature subsiding are more likely to progress to DHF. Clinical deterioration 
usually occurs during defervescence  (often between days 3 and 4)(20). Tachycardia and hypotension 
characterize the onset of plasma leakage. When plasma leakage is severe patients may develop other 
signs of circulatory disturbance such as prolonged capillary refill time, narrow pulse pressures, and 
shock. Inadequate treatment of such patients often leads to profound shock. During the phase of plasma 
leakage (first  24–48 hours after  onset  of DHF),  pleural effusions and ascites are  common. Pleural 
effusions are usually seen on the right side; a right decubitus chest radiograph is best for detecting 
small  effusions.  Abdominal  ultrasound  scans  may demonstrate  ascites  or  a  thickened  gall  bladder 
wall(21). Pericardial effusions may also occur. This latter complication is uncommon, but is associated 
with high morbidity and mortality.
In DHF, bleeding may occur  from any site  and does not correlate  with the platelet  counts. 
Haemorrhagic manifestations usually occur once the fever has settled(21). Minor degrees of bleeding 
may  manifest  as  gum  bleeding  and  petechiae.  The  commonest  site  of  haemorrhage  is  the 
gastrointestinal  tract,  which manifests  as  haematemesis  or  melaena,  followed by epistaxis.  Vaginal 
bleeding is commonly reported in females(21). Convalescence in DHF is usually short and uneventful. 
The return of appetite is a good indicator of recovery.
 Dengue shock syndrome 
Dengue shock syndrome is associated with very high mortality (around 9.3%, increasing to 
47% in instances of profound shock)(22). Severe plasma leakage leading to dengue shock syndrome is 
associated with cold blotchy skin, circumoral cyanosis, and circulatory disturbances. Acute abdominal 
pain and persisting vomiting are early warning signs of impeding shock. Sudden hypotension may 
indicate the onset of profound shock (23).Prolonged shock is often accompanied by metabolic acidosis, 
which  may  precipitate  disseminated  intravascular  coagulation  or  enhance  ongoing  disseminated 
intravascular coagulation, which in turn could lead to massive haemorrhage. Dengue shock syndrome 
may be accompanied by encephalopathy due to metabolic or electrolyte disturbances.
COMPLICATIONS 
Severe  dengue  infections  may  give  rise  to  many  complications  such  as  liver  failure, 
disseminated  intravascular  coagulation,  encephalopathy,  myocarditis,  acute  renal  failure,  and 
haemolytic uraemic syndrome (2). Although these complications are generally rare, in recent years they 
have been reported with increased frequency. Whether this is a true rise or due to an increase in the 
total number of cases of DHF needs to be determined.
Liver failure
Since hepatocytes and Kupffer cells support viral replication, liver involvement is common in 
all forms of dengue infection.Its severity varies with the overall severity of the dengue infection. Levels 
of aspartate transaminase and alanine transaminase are significantly higher, and globulins significantly 
lower among patients with the more severe grades of DHF. Infection with DEN-3 or DEN-4 serotypes 
produce greater liver involvement (liver enzymes higher compared with infection with the other two 
serotypes)(39). Fulminant liver failure can occur due to hepatitis or focal necrosis of the liver causing 
hepatic encephalopathy and even death (40).
Encephalopathy
Encephalopathy has been reported in 0.5% of patients with DHF, and has a mortality rate of 
22%. Many factors contribute towards development of encephalopathy including: hepatic dysfunction, 
electrolyte imbalances, cerebral oedema (caused by vascular changes leading to fluid extravasation) 
hypoperfusion (due to circulatory disturbances), and dengue encephalitis (41). The dengue virus has 
been  isolated  from  the  cerebrospinal  fluid  of  some  patients  having  features  of  encephalitis. 
Furthermore, in mice, breakdown of the blood-brain barrier and direct viral infection of the brain has 
been shown to occur. There is suggestion that histamine might have a critical role in this process. Other 
neurological manifestations such as altered consciousness, seizures, spasticity of limbs,  hemiplegia, 
and a positive Kernig’s sign have also been reported in 5.4% of patients with dengue.
Myocarditis
Acute reversible myocarditis has been reported in patients with dengue infections. ST segment 
and  T  wave  changes  in  the  electrocardiogram  together  with  low  ejection  fractions  and  global 
hypokinesia on radionuclide ventriculography have been found. No myocardial necrosis was detected 
in  any of  the  patients.  In  another  study,  16.7% of  children  had  left  ventricular  dysfunction  when 
assessed by two dimensional and colour Doppler echocardiography. The left ventricular failure may 
contribute to hypotension seen in DHF/dengue shock syndrome and may have implications in fluid 
management as fluid overload may worsen the condition.
PATHOGENESIS OF DENGUE FEVER/DHF
Dengue may be caused by any of the dengue viral  serotypes.  Generally,  infection with one 
serotype  confers  future  protective  immunity  against  that  particular  serotype  but  not  against  other 
serotypes.  Furthermore,  when infected  for  a  second time with a  different  serotype,  a  more severe 
infection may occur. This is due to a phenomenon referred to as antibody dependent enhancement, 
where antibodies against the first serotype enhance infection with the second serotype. However, as 
only  2%–4%  of  individuals  with  a  secondary  dengue  infection  develop  severe  disease,  antibody 
dependent enhancement alone cannot wholly explain this process (4). At present, reasons as to why 
only some individuals  develop symptomatic  infection  are  not  known,  but  active  research  is  being 
pursued by several groups to clarify such mechanisms. 
After the bite of an infected mosquito, the dengue virus enters the body and replicates within 
cells  of  the  mononuclear  phagocyte  lineage  (macrophages,  monocytes,  and  Bcells).  Additionally, 
infection of mast cells, dendritic cells, and endothelial cells are known to occur. The incubation period 
of dengue infections is 7–10 days. A  viraemic phase follows where the patient becomes febrile and 
infective. Thereafter, the patient may either recover or progress to the  leakage  phase, leading to DHF 
and/or dengue shock syndrome. Peak plasma viraemia correlates with the severity of dengue infections. 
Differences in antibody, cytokine, and T-cell responses are seen among patients with uncomplicated 
dengue fever or DHF/dengue shock syndrome. 
RISK FACTORS
Several risk factors have been proposed for development of DHF. These include: serotype and 
virulence of the infecting dengue virus, age, sex, immune status, and genetic background of the host 
(2,4). Case fatality and hospitalization rates due to DHF/dengue shock syndrome are highest in infants 
and the elderly. For instance, following a secondary DEN-2 infection, the risk of death in children is 
nearly 15-fold higher than that in an adult(27). DHF is also reported to be more severe among females 
(28).
Generally  malnutrition  predisposes  to  many  infectious  diseases  (for  example,  measles  or 
tuberculosis) and tends to correlate positively with severity of disease. However, malnutrition appears 
to be significantly uncommon among patients with DHF, compared with patients with other infectious 
diseases or healthy children(29).
DHF tends to be commoner among patients suffering from other chronic illnesses (for example, 
diabetes mellitus or bronchial asthma)(27,28). The DEN-2 virus is capable of replicating better within 
peripheral blood mononuclear cells from asthmatics than non-asthmatics. Further investigation of these 
different factors should help us better understand the pathogenesis of DHF and may in turn allow us to 
identify possible therapeutic options.
HOST GENETIC INFLUENCES IN DENGUE VIRAL
INFECTIONS
Severe dengue infections  are  seen  in  only a  minority (2%–4%) of  patients  with secondary 
dengue infections (4). Human genetic factors have been little studied in DHF, but the small proportion 
of antibody positive persons who develop DHF, a possible racial difference in susceptibility, and a few 
studies  suggesting  HLA  associations  provide  support  for  some  genetic  component  to  variable 
susceptibility. For instance, in Haiti, despite hyperendemic transmission of dengue fever, DHF is not 
reported(30).Furthermore, in Africa, where all four dengue viral serotypes circulate and epidemics of 
dengue fever occur, few cases of DHF are seen(4).
LAB DIAGNOSIS OF DENGUE INFECTIONS
Virus isolation
* Mosquito cell lines.                                                             
 * Mosquito inoculation technique.
* Vertebral cell culture.
Serological diagnosis
* Haemagglutination inhibition test.                                                                         *ELISA.
* Complement fixation test.                                                                               *
Neutralization test.                                                                                                 *
Antigen capture enzyme immunosorbent assay. 
Molecular diagnostic methods
* RT-PCR. 
PRIMARY AND SECONDARY DENGUE 
In primary dengue infections, 80% of patients demonstrate Ig M antibodies by day 5, and 99% 
by day 10 to 20.  Ig M antibodies peak at 2 weeks and decline over the next 2 to 3 months.  Ig G 
antibodies rise later and to lower levels as compared to Ig M, then decline gradually but persist at low 
levels for life.
            In secondary dengue infections, there is a brisk and rapid Ig G response much higher than that  
seen in primary infections, which peaks at 2 weeks and then declines   slowly  over the next 3 to 6  
months. Ig M response in secondary infections is slower and lower than Ig G with some individuals 
showing no detectable Ig M.
A Rough Guide for Interpretation of Dengue Serology Reports (42).
Ig M Ig G Interpretation
Negative Negative Early sample/ Not dengue
Negative Positive(low titer) Past dengue infection
Negative Positive(high titer) Secondary dengue
Positive Negative Primary dengue
Positive Positive(low titer) Current/  Recent  primary 
dengue
Positive Positive Secondary dengue
Serological diagnosis
Methods  used  for  serological  diagnosis  of  dengue  infections  include:  haemagglutination 
inhibition  tests,  enzyme  linked  immunosorbent  assay  (ELISA),  complement  fixation  test  and 
neutralization tests. Dengue specific IgM and IgG ELISA is widely used, as it is relatively inexpensive,  
has  good  sensitivity,  and is  quick  and  simple  to  perform(2).  Most  patients  have  measurable  IgM 
antibodies by the fifth day of infection. On average, they become undetectable 30–60 days after the 
onset  of  illness.  The  sensitivity  of  Ig  M ELISAs  range  from 83.9%–98.4% with  a  specificity  of 
100%(27). The range of sensitivities may be important in patients with secondary dengue where Ig M 
antibody titers are low (31). Antigen capture ELISAs have also been developed. The serotype of the 
infecting virus can also be identified using conventional or capture ELISAs (32).
The ability of dengue viruses to agglutinate goose erythrocytes is used in the haemagglutination 
inhibition test. A fourfold or greater rise in antibody titers is suggestive of a flavivirus infection (and 
not diagnostic of dengue infections).However, a single antibody titer >1/2560 is accepted as indicating 
secondary dengue infection if supported by a clinical history suggestive of dengue.
Molecular detection
The sensitivity, specificity, and rapid detection of minute quantities of dengue viral material in 
the patient’s serum makes RT-PCR useful for the detection of dengue infection early in the disease 
when antibodies are not detected (33). RTPCR is more sensitive than virus isolation, allows for rapid 
detection of dengue infections (results are usually available in 24 hours) and easier identification of the 
circulating serotype(33) It is useful for epidemiological studies as dengue serotypes could be identified 
without cross reactivity with other flavi viruses.
CASE DEFINITION (2)
The WHO has developed the following case definitions for the diagnosis of DF and DHF or 
DSS.
Dengue Fever
The clinical description of DF is an acute febrile illness of 2-7 days duration associated with 2 or more  
of the following  
 Headache
 Retro orbital pain
 Myalgia /Arthralgia 
 Rash
 Hemorrhagic manifestations
 Leucopenia    
Suspected 
Cases are classified as suspected if they are compatible with the clinical description described 
above.
Probable 
Cases are classified as probable if they are compatible with the clinical definition and satisfy one or 
more of the following criteria: 
• Supportive serology (reciprocal hemagglutination-inhibition antibody titer greater than 1280, 
comparable Ig G EIA titers, or positive Ig M antibody test in late acute or convalescent-phase 
serum specimen) 
• Occurrence at the same location and time as other confirmed cases of DF
Confirmed
A confirmed case is one that is compatible with the clinical definition and is confirmed by the 
laboratory by any one of the following.
 Isolation of Dengue virus from serum or autopsy sample.
 Demonstration of fourfold or more rise in Ig G or Ig M antibody titers.
 Demonstration  of  virus  antigen in  serum,  CSF  or  autopsy  sample  by 
Immunohistochemistry or ELISA.
 Detection of Dengue virus genome in serum, CSF or autopsy sample by PCR.
Dengue Hemorrhagic Fever:
Criteria for the diagnosis of DHF include a probable or confirmed case of dengue infection and 
hemorrhagic tendencies as evidenced by one or more of the following: 
 A positive result from the tourniquet test 
 Petechiae, ecchymoses, or purpura 
 Bleeding from the mucosa, gastrointestinal tract, injection sites, or other sites 
 Hematemesis or melena 
 Thrombocytopenia (<100,000 cells/mm3) and
 evidence of plasma leakage due to increased vascular permeability manifested by one or more 
of the following: 
• greater than 20% rise in average Hematocrit level for age and sex, 
• greater than 20% drop in Hematocrit level following volume replacement compared to 
baseline, or 
• signs of plasma leakage (e.g., pleural effusion, ascites, hypoproteinemia) 
Dengue Shock Syndrome
DSS is diagnosed in cases meeting  all of the above criteria plus evidence of circulatory failure, 
such as the following: 
• Rapid, weak pulse 
• Narrow pulse pressure (<20 mm Hg) 
• Hypotension 
• Cool, clammy skin 
• Altered mental status
Grading of DHF
Grade I
 FEVER  +  NON  SPECIFIC  CONSTITUTIONAL SYMPTOMS,  POSITIVE  TOURNIQUET 
TEST.
Grade II
GRADE 1 MANIFESTATIONS + SPONTANEOUS BLEEDING
Grade III
ABOVE SIGNS + CIRCULATORY FAILURE.
Grade IV
PROFOUND SHOCK.
Lab Studies 
Complete blood cell count findings include the following:
• Leukopenia, often with lymphopenia, is observed near the end of the febrile phase of illness. 
Lymphocytosis, with atypical lymphocytes, commonly is seen before defervescence or shock.
• A rise in Hematocrit greater than 20% is a sign of hemoconcentration and precedes shock. 
The Hematocrit level should be monitored at least every 24 hours to facilitate early recognition 
of dengue hemorrhagic fever (DHF) and every 3-4 hours in severe cases of DHF or dengue 
shock syndrome (DSS).
• Thrombocytopenia has been demonstrated in up to 50% of dengue fever (DF) cases. Platelet 
counts of less than 100,000 are seen in DHF or DSS and occur before defervescence and the 
onset of shock. The platelet count should be monitored at least every 24 hours to facilitate early 
recognition of DHF.
• Basic metabolic panel findings include the following:
 Hyponatremia is the most common electrolyte abnormality observed in patients with DHF 
or DSS.
 Metabolic acidosis is observed in those with shock, and it must be corrected rapidly.
 Elevated BUN is observed in those with shock.
• Liver function test findings include the following:
• Mild elevations in transaminase levels may be seen.
• Low albumin is a sign of hemoconcentration.
• Coagulation  studies may  help  guide  therapy  in  patients  with  severe  hemorrhagic 
manifestations. Findings are as follows:
 Prothrombin time is prolonged.
 Activated partial thromboplastin time is prolonged.
 Low  fibrinogen  and  elevated  fibrin  degradation  product  levels  are  signs  of 
disseminated intravascular coagulation.
• Typing and  cross matching of blood should be performed in cases of severe DHF or DSS 
because blood products may be required.
• Serum specimens should be sent to the laboratory for serodiagnosis, polymerase chain reaction 
(PCR), and viral isolation. Because the signs and symptoms of DF are nonspecific, attempting 
laboratory confirmation of dengue infection is important. Serodiagnosis is made based on a rise 
in antibody titer in paired immunoglobulin G (IgG) specimens or immunoglobulin M (IgM). 
Results vary depending on whether the infection is primary or subsequent. The IgM capture 
enzyme-linked immunosorbent assay (MAC-ELISA) has become the widely used assay.
Treatment of Dengue & DHF (2,39): 
Febrile Phase:
In the initial phase the treatment of DF & DHF is the same and is as that of any other viral fever, i.e. 
symptomatic and supportive.
 Rest.
 Paracetamol (not > than 4 times in 24 hrs) according to age and weight for fever above 39°C.
 Do not   give Aspirin or Brufen. Aspirin can cause gastritis and/or bleeding. In children, Reye’s 
syndrome (Encephalopathy) may be a serious complication.
 Do not give antibiotics as these do not help.
 Oral Rehydration Therapy is recommended as there may be mild to moderate Dehydration 
due to vomiting & high temperature.
 Food can be given as per appetite.
Dengue Hemorrhagic Fever
Patients with known or suspected DF should have their platelet count and Hematocrit measured 
daily from the third day of illness until  1-2 days after defervescence.  Those patients with a rising 
hematocrit or falling platelet count should have intravascular volume deficits replaced. Those patients 
who improve can continue to be monitored in an outpatient setting. Those patients who do not improve 
should be admitted to the hospital for continued hydration.
Other indications of Hospitalization include:
 Patients who develop signs of Tachycardia
 ↑ CRT ( > 2 sec)
 Cool and clammy extremities
 Diminished peripheral pulses
 Changes in Mental status
 Oliguria 
 Sudden rise in hematocrit
 Narrowing of pulse pressure ( < 20 mm Hg )
 Hypotension ( Late finding-Uncorrected shock )
Intravascular volume deficits should be corrected with isotonic fluids such as Ringer lactate solution. 
Boluses of 10-20 ml/kg should be given over 20 minutes and may be repeated. If this fails to correct the 
deficit,  the hematocrit  value should be determined,  and,  if  it  is  rising,  limited clinical  information 
suggests that a plasma expander may be administered. Starch, dextran 40, or albumin 5% at a dose of 
10-20 ml/kg may be used. If the patient does not improve after this, blood loss should be considered. 
Patients with internal or gastrointestinal bleeding may require transfusion. Patients with coagulopathy 
may require fresh frozen plasma.
After patients with dehydration are stabilized, they usually require intravenous fluids for no 
more than 24-48 hours. Intravenous fluids should be stopped when the hematocrit level falls below 
40% and adequate intravascular volume is present. At this time, patients reabsorb extravasated fluid 
and are at  risk for  volume overload if  intravenous fluids  are  continued.  Do not  interpret  a falling 
hematocrit value in a clinically improving patient as a sign of internal bleeding. 
Fluid therapy DHF grades I and II
                                                        DHF grade I & II
             
initiate IV at 6 ml/kg/hr for 1-2 hrs
Improvement No Improvement
Reduce IV 3 ml/kg/hr             Increase IV 10 ml/kg/hr
for 6-12 hrs        1-2 hours
Improvement Improvement                                     No Improvement
Discontinue IV Reduce IV to                 HCT ↑            HCT ↓ 
after 24 hrs                6ml/kg/hr and
3ml/kg/hr and                  IV colloid              whole blood
stop after 48 hrs              10ml/kg/hr             10ml/kg/hr
                       dur: 1 hour            dur: 1 hour
                     Improvement
IV therapy to crystalloids as detailed
above from 10 to 6 to 3 ml/kg/hr and
stop after 48 hours
DHF  Grade III and IV
                                                Unstable vital signs
             Signs of profound Shock
Initiate IV crystalloids 10-20 ml/kg as bolus
Repeat if necessary (max 20-30 ml/kg)
Improvement No Improvement
IV crystalloids  ↓ to     HCT ↑↑                                                 HCT  ↓↓
10 to 6 to 3 ml/kg/hr
and stop after 48 hours
IV colloid         Blood transfusion
     or Plasma 10-20 ml/kg                    10 ml/kg/hr
     Bolus. Repeat if necessary
     max ( 30-40 ml/kg)
Improvement
IV crystalloids 20-10-6-3 & stop after 48 h
Fluids Recommended:
Crystalloids :
  5% Dextrose in Isotonic NS
  5% Dextrose in ½ NS
  5% Dextrose in RL
  Shock Correction NS or RL 
Colloids :
  Dextran 40
  Hemaccel 
 Plasma
Fluid Replacement
 Volume of fluid to be just  sufficient  to  maintain effective circulation during plasma 
leakage.
 Fluid charts to be made every 1 to 3 hrs and even more frequently in shock.
Change should not be drastic. e.g. don’t jump from 20 ml to 6ml or vice versa. Go in a step wise 
manner.
Indications of Platelet / Whole blood transfusion (2)
Platelets
 Platelet count < 20,000/ cu.mm
 Platelet count >20,000 <40,000 with hemorrhagic manifestations.
 DIC
Whole Blood
 Prolonged refractory shock with ↓↓HCT even with adequate fluid replacement
 Severe massive bleeding ( > 10 % of total blood volume).
Indications of FFP 
(Fresh frozen Plasma)
 Plasma is used when HCT is rising despite fluid replacement
 But plasma substitutes are equally good (Dextran 40) & effective
 Essential only in cases of massive bleeding with DIC.
Monitoring of patients in DSS
 Check vitals every 15-30 minutes until shock is overcome.
 Check HCT / Platelets for every 2 hours for the first 6 hours and every 4 hours until  
stable.
 Fluid  balance  sheet  to  be  maintained.  Frequency  &  volume  of  urine  output  to  be 
recorded. In refractory shock catheter may be needed.
Criteria for Discharge (2)
Patients  who  are  resuscitated  from  shock  recover  rapidly.  Patients  with  DHF  or  dengue  shock 
syndrome (DSS) may be discharged from the hospital when they meet the following criteria:
 Afebrile for 24 hours without antipyretics 
 Good appetite, clinically improved condition 
 Adequate urine output 
 Stable hematocrit 
 At least 48 hours have passed since recovery from shock 
 Absence of respiratory distress 
 Platelet count greater than 50,000.
PREVENTION AND CONTROL OF DHF
Since  there  is  no  effective  vaccine  against  dengue,  the  prevention  and  control  of  dengue 
infections depends largely on preventing man-vector contact. Numerous strategies have been adopted 
and include: environmental control, biological control, chemical control, and active case surveillance. 
While each of these methods have some effect, successful control programmes should incorporate all 
appropriate methods and also foster a strong partnership between the different dengue control agencies 
and the community. The dengue control programmes in the South East Asian and South Asian regions 
have been generally unsuccessful, largely because they have relied solely on insecticide spraying(2).
Environmental control methods
         These include: reducing vector breeding sites, solid waste management, modification of man 
made breeding sites, and improvements in house design. Public education programmes play a vital part  
if  they are to  be effective (35).  Personal  protection is  important  in preventing man-vector  contact. 
Sufficiently thick and loose fitting clothes reduce contact with the mosquitoes, but may not be the most 
practical clothes to wear in hot tropical climates. Other measures such as using household insecticidal 
products (mosquito mats and liquid vaporizers) or mosquito repellents may also be effective. Naturally 
occurring repellents (citronella oil, lemon grass) or chemical repellents (DEET) are available. However, 
unlike in the control of malaria, insecticide treated mosquito nets have limited utility in dengue as the  
vector is chiefly a day biting mosquito.
Biological control of vector
             Biological control methods are targeted against the larval stages of the dengue vector. They 
include  the  use  of  larvivorous  fish  such  as  Gambusia  affinis  and  Poecilia  reticulate,  endotoxin 
producing bacteria (Bacillus thuringiensis serotype H-14 and Bacillus sphaericus are currently used), 
and copepod crustaceans. Bacillus thuringiensis serotype H-14 is more effective against A aegypti with 
very low levels of mammalian toxicity, and has therefore been accepted for use in household containers 
storing water.2 The use of mesocyclops (a copepod crustacean) in the Northern Province of Vietnam 
led to the eradication of the vector in a many areas(36).
Chemical control
This includes the application of larvicidal insecticides or space spraying.  Space spraying is 
more widely used as larvicidal insecticides cost more. Insecticides used for treating containers that hold 
water  includes  Temephos  1% sand  granules  and  insect  growth  regulators.  Regular  monitoring  of 
resistance  patterns  is  essential  as  resistance  to  Temephos  has  been  reported  among  some  aedes 
mosquito  species  in  the  South  East  Asian  Region  (2).  Insect  growth regulators  interfere  with  the 
development of the immature forms of the mosquito and have extremely low mammalian toxicity. 
Space spraying may be applied as thermal fogs or as ultralow volume sprays. Although both methods 
are equally effective in killing adult mosquitoes, thermal fogging tends to be used more widely(37).
Current status of the dengue vaccine
Much research has been carried out to develop a dengue vaccine that is safe and immunogenic 
against all four serotypes. Although many of the vaccines developed so far (live attenuated, chimeric, 
DNA, and subunit vaccines) show promising results, none are sufficiently immunogenic for routine use 
(38).
OBSERVATIONS AND RESULTS
105 seropositive dengue cases were reported in our hospital during the study.
Dengue fever  : 24 (22.8%)
Dengue fever with unusual bleeds : 32 (30.4%)
Dengue hemorrhagic fever  : 29 (27.6%)
Dengue shock syndrome: 20 (19.04%)
The age group of the affected children was between 5 months to 12 years.( Mean 5.6 year, 
standard deviation 3.2 ). DSS occurred at a relatively younger age group (mean 4.04 years). But it was 
statistically not significant (P=0.32). Infants comprised 10.4%   of total study group. 40% were children 
between 1 and 5 years of age. 49.5% were children between 5 and 12 years. Mean duration of fever 
was 5.09 days. It  was 4.95, 5.25, 5.24, 4.8 days in DF, DFB, DHF, DSS respectively.  Males were 
affected slightly more than females. It was not significant (P=0.70).
TABLE - 1
CLINICAL FEATURES
No Feature Total DF DFB DHF DSS P 
value
1 Mean age(yr),
(S.D)
5.6(3.2) 6.1(3.9) 5.7(3.1) 6.1(3.2) 4.04(3.39) 0.32
2 Male sex, 
no(%)
56(53) 11(45) 17(53) 18(62) 10(50) 0.70
3 Age ≤1yr, 
no(%)
11(10.4) 1(4.1) 3(9.4) 1(3.4) 6(30) 0.216
4 1-5 yr, no(%) 42(40) 11(45.8) 11(34.4) 13(44.8) 7(35) 1.0
5 5-12yr,no(%) 52(49.5) 13(54.1) 17(53.1) 15(51.7) 7(35) 0.43
6 Mean 
duration of 
fever, 
days(S.D)
5.09(2.3
)
4.95(2.1
)
5.25(2.5
)
5.24(1.8
)
4.8(2.7) 0.34
Most  common  manifestations  were  fever(100%),  vomiting(81.9%),  bleeding 
manifestations(77.14%), rashes(64.7%) and myalgia(62.8%). 
 Fever was continuous, biphasic, and intermittent in 70.4, 20.9 and 8 percentages respectively.
Myalgia was less commonly noted in DSS. But it was statistically not significant (P=0.47).
TABLE 2   
CLINICAL FEATURES
N
o
Feature Total DF DFB DHF DSS P 
value
1 Fever,no(%) 105(100) 24(100) 32(100) 29(100) 20(100) _
2 Myalgia,no(%) 66(62.8) 16(66.6) 23(71.8) 21(72.4) 6(30) 0.47
3 Headache,no(%) 22(20.9) 4(16.6) 5(15.6) 9(31) 4(20) 0.53
4 Abd.pain,no(%) 39(37.1) 5(20.8) 9(28.1) 19(65.5) 6(30) 0.41
5 Vomiting,no(%) 86(81.9) 16(66.6) 25(78.1) 25(86.2) 20(100) 0.0049
6 Altered 
sensorium,no(%)
68(64.7) 7(29.1) 17(53.1) 24(82.7) 20(100) 0.023
Vomiting was present in all DSS children (100%). When compared to DF group (66.6%) it is 
statistically significant (P=0.0049). All DSS had altered sensorium (100%). When compared to DF 
group  (29.1%), it is statistically significant (P=0.023).
TABLE-  3
BLEEDING PROFILE
N
o
Feature Total DF DFB DHF DSS P value
1 Epistaxis, no(%) 2(1.9) 0(0) 1(3.1) 1(3.4) 0(0) 0.82
2 Malena, no(%) 12(11.4) 0(0) 6(18.75) 4(13.8) 2(10) 0.65
3 Hematemesis, 
no(%)
12(11.4) 0(0) 4(12.5) 4(13.8) 4(20) 0.73
4 IV bleed, no(%) 0(0) 0(0) 0(0) 0(0) 0(0) _
5 Petechiae, no(%) 18(17.1) 0(0) 13(40.6) 5(17.2) 0(0) 0.61
6 Purpura, no(%) 1(0.95) 0(0) 1(3.1) 0(0) 0(0) _
7 Ecchymosis,no(%) 0(0) 0(0) 0(0) 0(0) 0(0) _
8 >1 site,no(%) 
(hematemesis+ 
petechiae)
36(34.3) 0(0) 7(21.9) 15(51.7) 14(70) 0.001
9 None 24 0 0 0 0 _
            Out of 105 children ,81 had one or more form of bleeding manifestations. Bleeding from more  
than  one  site  was  the  most  common  manifestation  (P=0.001).  Petechiae(17.1%),tourniquet  +ve 
test(26.7%),  hematemesis(11.4%),  malena(11.4%),  epistaxis(1.9%),purpura(0.95%)  were  other 
manifestations.
     Hepatomegaly was present in 90% in DSS and 86.2% in DHF. It was statistically significant  
when compared with DF and DFB (P=0.0219).
TABLE 4 CLINICAL FEATURES
No Feature Total DF DFB DHF DSS P value
1 Hepatomegaly, no(%) 53(50.5) 3(12.5) 7(21.9) 25(86.2) 18(90) 0.0219
2 Tourniquet +, no(%) 28(26.7) 0(0) 9(28.1) 12(41.4) 7(35) 0.35
3 Shock, no(%) 21(20) 1(4.1) 0(0) 0(0) 20(100) 0.001
4 3rd spacing, no(%) 49(46.6) 0(0) 0(0) 29(100) 20(100) _
One DF child  presented with shock. But there were no signs suggestive of plasma leakage. 
That child had improved with two boluses 0f normal saline. 
Third spacing was seen in 49 children (46.6%).In DHF, 6 had only pleural effusion, 23 had both 
pleural effusion and ascites.  
In DSS 2 had only pleural effusion, 18 had both pleural effusion and ascites. Pleural effusion 
was bilateral in 2 children.TABLE:  5
CLINICAL FEATURES
No Feature Total DF DFB DHF DSS
P 
valu
e
1 Rash, no(%) 68(64.7
)
15(62.5
)
21(65.6
)
18(62
)
14(70
)
0.57
2 Seizures,no(%) 10(9.5) 3(12.5) 1(3) 2(6.8) 4(20) 0.47
3 Loose stools, no(%) 9(8.5) 5(21) 1(3) 1(3) 2(10) 0.89
4 Bradycardia, no(%) 9(8.5) 4(16.6) 3(9.3) 2(6.8) 0(0) 0.78
5 Lymphadenopathy, 
no(%)
16(15.2
)
12(50) 1(3.1) 2(6.8) 1(5) 0.46
Seizures (9.5%), loose stools (8.5%), lymphadenopathy (15.2%), relative bradycardia (8.5%) 
were less common manifestations. Rashes were seen in 64.7% of children. 
Many children in this study were mildly anemic. Mean hemoglobin was slightly higher in DHF 
and DSS.  
Mean Hb in DSS was 11.28g%. It was 10.02, 10.1,   and   10.45 in DF, DFB, DHF  respectively. 
But it was statistically not significant (P=0.27). 
TABLE - 6
Hb & PCV
No Feature Total DF DFB DHF DSS P value
1 Hb 
mean(S.D)
10.4(1) 10.02(1.05
)
10.1(0.95
)
10.45(0.9
)
11.28(0.59
)
0.27
2 Hematocrit 
mean(S.D)
34.06
(5.5)
30.8(2.6) 30.65(2.8
)
37.27(6.9
)
38.75(1.11
)
0.014
1
As many children were mildly anemic, the mean hematocrit value also relatively low. In DHF 
and DSS mean hematocrit was significantly higher than classical DF and DFB (P=0.0141).  In DFB, 
DHF ,DSS low platelet counts correlate with bleeding manifestations(P=0.025).
            SGOT and SGPT levels were elevated in all groups. Elevation of SGOT and SGPT were 
significantly higher in DHF and DSS when compared with classical dengue and DFB (P=0.001).
TABLE - 7
PLATELET COUNT (per cu.mm)
No Feature Total DF DFB DHF DSS P value
1 >1 lakh,no(%) 3(2.8) 3(12.5) 0(0) 0(0) 0(0) 0.9
2 40000-1 lakh,no(%) 33(31.4) 17(70.8) 14(43.8) 2(6.9) 0(0) 0.37
3 20000-39999,no(%) 53(50.5) 4(16.6) 18(56.2) 19(65.5) 12(60) 0.025
4 <20000,no(%) 16(15.2) 0(0) 0(0) 8(27.6) 8(40) 0.013
TABLE -  8
SGOT & SGPT
No Feature Total DF DFB DHF DSS P value
1 SGOT & 
SGOT,no(%)
(>50IU/L)
75(71.4) 12(50) 17(53.1) 26(89.6) 20(100) 0.001
TABLE - 9
ULTRASOUND ABDOMEN
N
o Feature Total DF DFB DHF DSS
P 
value
1 Hepatomegaly,no(%) 56(53.3) 2(8.3) 6(18.75)
28(96.5
)
20(100
)
0.001
7
2 Polyserositis,no(%) 16(15.2) 0(0) 1(3.1) 10(34.4) 5(25)
0.003
2
3 Gall bladder wall thickening,no(%) 26(24.7) 0(0) 0(0)
13(44.8
) 13(65) 0.001
4 Ascites,no(%) 41(39.04) 0(0) 0(0)
23(79.3
) 18(90) 0.001
5 Normal study,no(%) 49(46.6) 22(91.6)
26(81.25
) 1(3.4) 0(0) 0.001
In ultrasound abdomen, DHF (96.5%) and DSS (100%) had hepatomegaly. It is statistically 
significant when compared with DF and DFB (P=0.0017). Polyserositis  also significantly more in 
DHF and DSS group(P=0.0032).
Gall bladder wall thickening was noted in 44.8% in DHF and 65% in DSS. No children in DF 
or DFB had gall bladder wall thickening. It is statistically significant (P=0.001). 49 children had no 
abnormalities in ultrasound abdomen. Children in DF and DFB had more reports of normal ultrasound 
abdomen (P=0.001).No children in DSS group had normal study.
TABLE-10
OUTCOME
No Feature Total DF DFB DHF DSS P value
1 Recovery,no(%) 103(98.1) 24(100) 32(100) 29(100) 18(90) 0.0348
2 Death,no(%) 2(1.9) 0(0) 0(0) 0(0) 2(10) 0.0348
Out of 105 children, 103 were recovered from the illness. Two children from DSS group died.  
Both were brought to the hospital very late. Duration of hospital stay was less than 24 hours in both the  
children. Overall recovery rate was 98.1%. IN DF, DFB, DHF all children were recovered. Recovery 
rate in non-DSS group was significantly higher than DSS (P=0.0348). Mortality due to DSS was 10%. 
This is significantly higher than non-DSS group (P=0.0348). Overall mortality was 1.9%. 
DISCUSSION
The relationship of dengue with India has been long and intense. The first recorded epidemic of  
clinically dengue like illness occurred at Madras (Chennai) in 1780 and the dengue virus was isolated 
for the first time almost simultaneously in Japan and Calcutta 1n 1943-44. Then it spread to all over the 
country.  The first  full  blown epidemic of severe form of dengue occurred in North India in 1996. 
Every year the epidemiology and clinical manifestations are changing. Here I compare the clinical 
profile and outcome of dengue with other Indian and foreign studies.
Total of 105 cases of seropositive dengue children presented at Institute of Social Pediatrics 
were  analyzed.  According  to  WHO classification,  Dengue  fever(  including  DFB)(53.2%),  Dengue 
hemorrhagic fever(27.6%), Dengue shock syndrome(19.04%) was seen.
          Kabilan et al (Chennai 2001) reported DF(65.5%),DHF(11.2%), DSS(23.8%). Ratageri et al  
(Hubli  2003)  reported  DF(18%),DHF(60%),DSS(22%).  Narayanan  et  al  (Chennai  2001)  reported 
DF(72.78%),  DHF(18.6%),DSS(8.4%).  Kalyanarooj  et  al(Indonesia)  reported  DF (including  DFB)
(53%), DHF(including DSS)(47%).  In  present study, DHF( including DSS) is 46.64%.Present  study 
is comparable with other studies.
        Incidence of DHF and DSS was increased when comparing   the study by Narayanan (2001). It 
may be due to increasing endemicity, environmental factors and changing virulence of the viruses.
AGE
         In present  study, infants (10.4%), 1-5 years (40%), 6-12 years(49.5%) was observed. Kabilan et  
al reported 20%, 28.7% for infants and 1-5 years group. He reported  that 6-15 years formed 51%. In 
present  study, <5years were 50.4%. More than 5 years were 49.5%.Aggarwal et al reported 45% & 
55% for the same groups. Infants are lesser in present study when comparing with Kabilan et al. 
SEX
No Study Male(%) Female(%)
1 Narayanan et al 52.4 47.6
2 Gomber et al 56 44
3 Aggarwal et al 60 40
4 Present  study 53 47
   
It is comparable with other studies.
 FEVER
Continuous (74%), Biphasic  (22%),  Intermittent  (9%) was seen in  the present  study.  Mean 
duration of fever was 5.09 days. Narayanan reported 4.9 days. It was lesser in DSS (4.8 days) and 
statistically not significant (P=0.34).
VOMITING
No Study Percentage
1 Kalyanarooj(Indonesia) 66
2 Ratageri(Hubli) 82
3 Narayanan(Chennai) 83
4 Present  study 81.9
It is comparable to other studies. It was significantly more common in DSS group(P<0.05).
HEMATEMESIS
No Study Percentage
1 Aggarwal et al 29
2 Narayanan et al 61
3 Ratageri et al 22
4 Present  study 45.75
Bleeding from more than one site( hematemesis+ petechiae) was the most common in present  study.  
Hematemesis was most common in other studies. Its percentage is variable in different studies. 
HEADACHE
       It was 28.8%(Narayanan), 77%(Kalyanarooj), 22%(Ratageri).
It  is 20.9% in the present  study. Younger kids may not complain this symptom. High 
percentage in Kalyanarooj’s study may be due to different age composition.
ALTERED SENSORIUM
      It was 65% by Ratageri and 23.7% by Narayanan. It is 64.7% in present  study. Low percentage 
in Narayanan may be due to lesser DHF and DSS.
ABDOMINAL PAIN
It is 37.1% in present  study and 34.5% in Kalyanarooj.  Aggarwal reported 49%. He studied 
only DHF and DSS and may be the   reason for high percentage.
HEPATOMEGALY
It was (72%) in Aggarwal, (52.5%) in Narayanan and (50.5%) in present  study. Hepatomegaly 
was significantly more common in DHF and DSS in all studies. 
TOURNIQUET  TEST
It  was  26.7%  in  Aggarwal,  25%  in  Gomber,  23.7%  in  Narayanan  and  52%  in 
Kalyanarooj(Indonesia). It is 26.7% in present  study. High percentage in Indonesia may be due to 
difference in skin complexion and capillary fragility.
SHOCK
No Study Percentage
1 Aggarwal et al 33
2 Gomber et al 20
3 Narayanan et al 8.4
4 Kabilan et al 23.8
5 Ratageri et al 22
6 Present  study 19.04
DSS was low in Narayanan et al. Due to increasing endemicity and changing epidemiology, DSS is  in 
increasing trend.
THIRD SPACING
It is 100% in DHF and DSS in present study. Kalyanarooj reported 84% in DHF. Narayanan et 
al reported low percentage as there was low DHF and DSS.
LYMPHADENOPATHY
It is 15.2% in present study and 10.2% in Narayanan et al.
MEAN HEMOGLOBIN
It is 10.4g% in present study. Narayanan  et al reported 10.8g%.
No Classification Present  study Narayanan et al
1 DF 10.02 10.8
2 DFB 10.1 11.1
3 DHF 10.45 10.3
4 DSS 11.28 11.4
MEAN HEMATOCRIT
Present study: 34.06%. Narayanan et al: 33.2%. Gomber et al reported 38.34%. In my study 
there is wide prevalence of mild anemia and low hematocrit. Mean hematocrit value was significantly 
higher in DHF and DSS group.
Hematocrit(mean)
No Classification Present  study Narayanan et al
1 DF 30.8 32.2
2 DFB 30.65 32.1
3 DHF 37.27 35.2
4 DSS 38.75 37.6
PLATELET COUNT
       In present study, >1 lakh= 2.85%,
                        40000-1 lakh=31.4%,
                        20000-39999= 50.5%,
                        <20000= 15.2%.
Aggarwal et al reported, 
                         >50000= 31%,
                      25000-50000=47%,
                    <25000= 22%.
Present  study is comparable with Aggarwal et al.
SGOT & SGPT
           They are elevated in 71.4%. Elevation in DHF and DSS was statistically more common than in 
DF and DFB. It was also seen in Aggarwal et al and Kalyanarooj et al.
ULTRASOUND ABDOMEN
No Study Ascites GBWT Hepatomegaly
1 Setiwan(Indonesia)      Mild dengue 34% 32% 49%
2 Setiwan(Indonesia) Severe dengue 95% 95% 95%
3 Srikiatkhachom(Indonesia) 52% 43% 57%
4 Venkata sai (Chennai) 53% 100% 21%
5 Present  study(DHF&DSS) 84.65% 54.9% 98.25%
GBWT= Gall bladder wall thickening.
 In severe dengue(DHF & DSS), ascites, gall bladder wall thickening and hepatomegaly were 
significantly more common in present  study(P<0.05). The above studies also reveal the same. GBWT 
more than 5 mm in clinically suspected dengue cases signifies 91.7% specificity towards DHF and 
DSS.
MORTALITY
According to Halstead et al, mortality due to dengue in Asian countries is  0.5%-3.5% ( if early 
recognition and appropriate treatment was instituted).
     Mortality in my study is 1.9%. 
     
No Study Mortality(%)
1 Kabra et al(1992) 12-13%
2 Srivastava et al (1990) 12-13%
3 Aggarwal et al (1996) 6%
4 Gomber et al (2001) 4.8%
5 Narayanan et al(2001) 3.3%
6 Kabilan et al(2001) No mortality
7 Ratageri et al (2003) No mortality
8 Present  study 1.9%
 
Mortality rate is drastically reduced by early recognition, precise assessment and appropriate 
fluid management as per WHO protocol.
LIMITATIONS OF THE STUDY
 1.  Confirmation  of  dengue  viral  infection  was  not  done.  So,  all  the  cases  in  the  study  are 
PROBABLE DENGUE according to WHO case definition.
 2. Viral antibody titers were not done to diagnose primary and secondary dengue precisely.
 3. Serotypes were not done. So the predominant serotype was not identified.
 4. Treatment modalities like type of fluid used, need for inotrope support, ventilator support, need 
for blood products were not studied.
CONCLUSIONS
1 . Dengue fever is becoming more prevalent in India. Incidence of Dengue shock syndrome is 
increasing.
2.  Vomiting, hematemesis, skin bleeds, altered sensorium , hepatomegaly, elevated SGOT, SGPT, 
gall  bladder  wall  thickening,   ascites,  pleural  effusion  following  the  period  of  fever 
defervescence strongly indicate Dengue hemorrhagic fever and dengue shock syndrome.
3.  The bleeding in dengue is not purely due to thrombocytopenia. It is due to multiple etiologies 
including vascular changes. 
4. No role for prophylactic platelet transfusion. 
5. Early recognition, precise assessment and appropriate treatment have reduced the mortality.
6. Parental health education about the fever defervescence and early referral may prevent deaths 
due to dengue.
ANNEXURES
BIBLIOGRAPHY
1. Pinheiro FP, Corber SJ. Global situation of dengue and dengue haemorrhagic fever and its 
emergence in the Americas. World Health Stat Q1997;50:161–8.
2. World Health Organisation. Prevention and control of dengue and dengue haemorrhagic fever: 
comprehensive guidelines. WHO Regional publication, SEARO, No 29, 1999.
3. Halstead SB. Is there an inapparent dengue explosion? Lancet 1999;353:1100-1. 
 4. Guzman MG, Kouri G. Dengue: an update. Lancet Infect Dis 2002;2:33–42.         
 5. Sukri NC, Laras K, Wandra T, et al. Transmission of epidemic denguehemorrhagic fever in 
easternmost Indonesia. Am J Trop Med Hyg2003;68:529–35
6. Nisalak A, Endy TP, Nimmanitya S, et al. Serotype-specific dengue virus circulation and 
dengue disease in Bangkok, Thailand from 1973 to 1999. Am J Trop Med Hyg 2003;68:191–
202.
7. Chareonsook O, Foy HM, Teeraratkul A, et al. Changing epidemiology of dengue hemorrhagic 
fever in Thailand. Epidemiol Infect 1999;122:161–6.
8. Ha DQ, Tien NT, Huong VT, et al. Dengue epidemic in Southern Vietnam, 1998. Emerg Infect 
Dis 2000;6:422–5.
9. Anonymous. Dengue in the WHO Western Pacific Region. Weekly Epidemiological Record 
1998;72:273–80.
10. Munasinghe DR, Amarasekera PJ, Fernando CF. An epidemic of dengue-like fever in Ceylon 
(chikungunya)—a clinical and haematological study. Ceylon Med J 1966;11:129–42.
11. Messer WB, Vitarana UT, Sivananthan K, et al. Epidemiology of dengue in  Sri Lanka before 
and after the emergence of epidemic dengue hemorrhagic fever. Am J Trop Med Hyg 
2002;66:765–73.
12. Libraty DH, Young PR, Pickering D, et al. High circulating levels of the dengue virus 
nonstructural protein NS1 early in dengue illness correlate with the development of dengue 
hemorrhagic fever. J Infect Dis 2002;186:1165–8 (Epub 16 September 2002).
13. Cardosa MJ, Wang SM, Sum MS, et al. Antibodies against prM protein distinguish between 
previous infection with dengue and Japanese encephalitis viruses. BMC Microbiol 2002;2:9 
(Epub 5 May2002).
14.  Thavara U, Tawatsin A, Chansang C, et al. Larval occurrence, oviposition behavior and biting 
activity of potential mosquito vectors of dengue on Samui Island, Thailand. J Vector Ecol 
2001;26:172–80.
15. Perich MJ, Davila G, Turner A, et al. Behavior of resting Aedes aegypti (culicidae: diptera) and 
its relation to ultra-low volume adulticide efficacy in Panama City, Panama. J Med Entomol 
2000;37:541–6.
16.  Narayanan M, Aravind MA, Thilothammal N, et al. Dengue fever epidemicin Chennai—a 
study of clinical profile and outcome. Indian Pediatr2002;39:
1027–33.
17.  Pancharoen C, Mekmullica J, Thisyakorn U. Primary dengue infection: what are the clinical 
distinctions from secondary infection? Southeast Asian J Trop Med Public Health 2001;32:476–
80.
18. Kalayanarooj S, Nimmannitya S, Suntayakorn S, et al. Can doctors make an accurate diagnosis 
of dengue infections at an early stage? Dengue Bulletin 1999;23:1–9.
19. Halstead SB, Lan NT, Myint TT, et al. Dengue hemorrhagic fever in infants: research 
opportunities ignored. Emerg Infect Dis 2002;8:1474–9.
20. Lucus GN, Karunatilaka DH, Wijesuriya AP, et al. Guidelines for management of dengue 
haemorrhagic fever (DHF). Sri Lanka: Sri Lankan College of Paediatricians, 2003.
21. Kalayanarooj S, Chansiriwongs V, Nimmannitya S. Dengue patients at the Children’s Hospital, 
Bangkok: 1995–1999. Review. Dengue Bulletin 2002;26:33–43.
22  Kabra SK, Jain Y, Pandey RM, et al. Dengue haemorrhagic fever in children in the 1996 Delhi 
epidemic. Trans R Soc Trop Med Hyg 1999;93:294–8.
23. Agarwal R, Kapoor S, Nagar R, et al. A clinical study of the patients with dengue hemorrhagic 
fever during the epidemic of 1996 at Lucknow, India. Southeast Asian J Trop Med Public 
Health 1999;30:735–40.
24.  King CA, Marshall JS, Alshurafa H, et al. Release of vasoactive cytokines by antibody-
enhanced dengue virus infection of a human mast cell/basophil line. J Virol 2000;74:7146–50.
25. Ling Jun Ho, Wang JJ, Shaio MF, et al. Infection of human dendritic cells by dengue virus 
causes cell maturation and cytokine production. J Immunol 2001;166:1499–506.
26.  Huang YH, Lei HY, Liu HS, et al. Dengue virus infects human endothelial cells and induces 
IL-6 and IL-8 production. Am J Trop Med Hyg 2000;63:71–5.
27. Guzman MG, Kouri GP, Bravo J, et al. Dengue hemorrhagic fever in Cuba, 1981: a 
retrospective seroepidemiologic study. Am J Trop Med Hyg 1990;42:179–84. Guzman MG, 
Kouri G, Bravo J, et al. Effect of age on outcome of secondary dengue 2 infections. Int J Infect 
Dis 2002;6:118–24.
28.  Kabra SK, Jain Y, Pandey RM, et al. Dengue haemorrhagic fever in children in the 1996 Delhi 
epidemic. Trans R Soc Trop Med Hyg 1999;93:294–8.
29.  Thisyakorn U, Nimmannitya S. Nutritional status of children with dengue hemorrhagic fever. 
Clin Infect Dis 1993;16:295–7.
30. Halstead SB, Streit TG, Lafontant JG, et al. Haiti: absence of dengue hemorrhagic fever despite 
hyperendemic dengue virus transmission. Am J Trop Med Hyg 2001;65:180–3.
31. Kuno G, Gubler DJ, Santiago de Weil NS. Antigen capture ELISA for the identification of 
dengue viruses. J Virol Methods 1985;12:93–103.
32.  Nawa M, Ichikawa Y, Inouye S. Serotyping of dengue viruses by an enzymelinked 
immunosorbent assay. Jpn J Med Sci Biol 1985;38:217–21.
33.  De Paula SO, Pires Neto RJ, Correa JA, et al. The use of reverse transcription-polymerase 
chain reaction (RT-PCR) for the rapid detection and identification of dengue virus in an 
endemic region: a validation study. Trans R Soc Trop Med Hyg 2002;96:266–9.
34.  Tripathi BK, Gupta B, Sinha RS, et al. Experience in adult population in dengue outbreak in 
Delhi. J Assoc Physicians India 1998;46:273–6.
35.  Van Benthem BH, Khantikul N, Panart K, et al. Knowledge and use of prevention measures 
related to dengue in northern Thailand. Trop Med Int Health 2002;7:993–1000.
36.  Kay BH, Nam VS, Tien TV, et al. Control of aedes vectors of dengue in three provinces of 
Vietnam by use of mesocyclops (copepoda) and community based methods validated by 
entomologic, clinical, and serological surveillance. Am J Trop Med Hyg 2002;66:40–8.
37. Gratz NG. Space sprays for the control of Aedes aegypti in South-East Asia and the Western 
Pacific. Dengue Bulletin 1999;24:80–4.
38  Perikov Y. Development of dengue vaccine. Dengue Bulletin 2000;24:71–76.
39. G N Malavige, dengue viral infections 588-601.
40.  Nguyen TL, Nguyen TH, Tieu NT. The impact of dengue haemorrhagic fever on liver function. 
Res Virol 1997;148:273–7.
41.  Cam BV, Fonsmark L, Hue NB, et al. Prospective case-control study of encephalopathy in 
children with dengue hemorrhagic fever. Am J Trop Med Hyg .
42. Vijay N Yewale IAP speciality series on pediatric infectious diseases ( Under IAP action plan 
2006).
ABBREVIATIONS
DF  : Dengue fever
DFB : Dengue fever with unusual bleeds
DHF  : Dengue hemorrhagic fever
DSS : Dengue shock syndrome
WHO :  World health organization
ELISA : Enzyme linked immunosorbent assay
Hb : Hemoglbin
PCV : Packed cell volume
SGOT   : Serum Glutamate Oxalo-acetate Transaminase
SGPT  : Serum Glutamate Pyruvate  Transaminase
NS proteins  : Non-structural proteins
FFP : Fresh Frozen Plasma
GBWT : Gall bladder wall thickening.
PROFORMA
Name
Age
Sex  
IP No
Address
Date of admission
Date of discharge
Fever type
Myalgia
Head ache
Abdominal pain
Vomiting
Epistaxis
Malena
Haemetemesis
Venepuncture bleed
Rash
Tourniquet test 
Altered sensorium
Seizures
Loose stools
Relative bradycardia
Hepatomegaly
Shock
Third spacing
Lymphadenopathy
Hb
PCV
TC
Platelet count
IgM
IgG
SGOT
SGPT
CXR
USG Abdomen
WHO Classification
Outcome.
                            
KEY TO MASTER CHART
Age(in years)     :
Sex     : M/F
Fever type : 1.continuous 2.biphasic 3.intermittent
Myalgia : 1.yes 2.no 3.not applicable
Headache : 1.yes 2.no 3.not applicable
Abdominal pain: 1. yes 2. no 3. not applicable
Vomiting : 1.yes 2.no 
Bleeding manifestations : 1.epistaxis 2.malena 3.haematemesis 4.venepuncture bleed 5.petechiae 
6.purpura 7.ecchymosis 8.bleeding from more than one site(hematemesis+petechiae).
Rash  : 1.yes 2.no
Tourniquet test : 1.positive 2.negative
Sensorium : 1.lethargy 2.drowsy 3.obtundation 4.stupor 5.coma
Seizures : 1.generalised 2.focal 3.none
Loose stools : 1.yes 2.no 
Relative bradycardia :  1. Yes 2. no 
Hepatomegaly : 1.yes 2.no 
Shock : 1. yes 2.no
Third spacing : 1.ascites 2.pleural effusion 3.both 4.none
Lymphadenopathy : 1.yes 2.no 
Hemoglobin :
Hematocrit :
Total count :
Platelet count : 1.<20000/cu.mm 2.20000 to 40000/cu.mm                3.>40000 to < 1 lakh/cu.mm 4. > 1 
lakh/cu.mm
Ig M :1. positive 2. negative
Ig G : 1.positive 2.negative 
SGOT >50 IU/L : 1.yes 2. no
SGPT >50 IU/L : 1.yes 2.no
Alkaline phosphatase > 200 IU/L : 1.yes 2.no
Pleural effusion in CXR  : 1.yes 2.no
USG Abdomen : 1.hepatomegaly 2.hepatomegaly+polyserositis 3.hepatomegaly+polyserositis+gall 
bladder wall edema                                         
 4. hepatomegaly+ gall bladder wall edema
WHO classification : 1.Dengue fever
                                     2.Dengue fever with unusual bleed
                                     3.Dengue hemorrhagic fever
                                     4.Dengue shock syndrome.
                                                                                                                                                     
Outcome : 1.recovered 2.died. 
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